HMG Co A production in liver is inhibited by
**Core Concept**
HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) is a key intermediate in the biosynthesis of cholesterol. The liver is the primary site of HMG-CoA production, where it serves as a precursor for cholesterol synthesis. The regulation of HMG-CoA production is crucial in maintaining cholesterol homeostasis.
**Why the Correct Answer is Right**
The production of HMG-CoA in the liver is primarily regulated by the enzyme HMG-CoA synthase. However, HMG-CoA production is also inhibited by statins, a class of lipid-lowering medications. Statins work by competitively inhibiting the enzyme HMG-CoA reductase, which is upstream of HMG-CoA synthase in the cholesterol biosynthesis pathway. By inhibiting HMG-CoA reductase, statins effectively decrease the production of HMG-CoA, leading to a reduction in cholesterol synthesis.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not accurately describe a known inhibitor of HMG-CoA production in the liver.
**Option B:** This option is incorrect as it is a known activator of HMG-CoA production, rather than an inhibitor.
**Option C:** This option is incorrect as it does not accurately describe a known inhibitor of HMG-CoA production in the liver.
**Clinical Pearl / High-Yield Fact**
Statins are widely used to lower cholesterol levels in patients at risk of cardiovascular disease. However, they can also have a range of side effects, including muscle pain and increased risk of diabetes. It is essential to carefully weigh the benefits and risks of statin therapy in individual patients.
**Correct Answer: D.**